Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)
Highly customized biocatalysts can transform active pharmaceutical ingredients (API) manufacturing processes by eliminating steps, increasing yield, and reducing solvent usage and waste. Furthermore, carefully designed multi-step, biocatalytic cascades can be assembled in single reactors to accomplish difficult chemical reactions under mild reaction conditions, which expands the capability, and the efficiency, of sustainable biocatalytic processes at large scale.Catalysis or biocatalysis?
For many of our global partners, optimized biocatalytic processes enabled by our engineered enzymes have reduced improved capital utilization, yield and quality attributes while achieving desired yield, and several pharmaceutical industry partners have taken the partnership even further and licensed our technology to develop and expand their in-house use of custom enzymes API production.
Out of 70+ programs and millions of variants analyzed, we offer our best-performing enzymes to you, available in grams to multi-ton scale. The Codex® Ketoreductase Screening Kit has been widely used in active pharmaceutical ingredients synthesis as well as other industrial research areas.
Discover more about our screening kit products.
A paper authored by Merck and Codexis in the June 2022 issue of the peer-reviewed journal Science, details the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates.Read Paper